How surgery affects the time to relapse and must be taken into consideration when evaluating the effectiveness of platinum-based chemotherapy.
- Published in:
- Cancer & Chemotherapy Reviews, 2025, v. 19, n. 1, p. 25
- By:
- Publication type:
- Article
Works matching IS 1885740X AND DT 2025 AND VI 19 AND IP 1
Results: 4
1
2
BRCA-mutated patient with first relapse between 6 and 12 months in the third line.
- Published in:
- Cancer & Chemotherapy Reviews, 2025, v. 19, n. 1, p. 18
- By:
- Publication type:
- Article
3
Relapse at 10 months after maintenance with poly(ADP-ribose) polymerase inhibitor: a case eligible for non-platinum second line therapy.
- Published in:
- Cancer & Chemotherapy Reviews, 2025, v. 19, n. 1, p. 11
- By:
- Publication type:
- Article
4
Introduction.
- Published in:
- Cancer & Chemotherapy Reviews, 2025, v. 19, n. 1, p. 1, doi. 10.24875/CCR.M25000002
- By:
- Publication type:
- Article